Evidence map›Paper›PMID 32354946›Full record

ArticleIn vivo (Athens, Greece)

Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon

Gen Ohara, Shinichiro Okauchi, Yuika Sasatani, Toshihiro Shiozawa, Hideyasu Yamada, Kunihiko Miyazaki, Hiroaki Satoh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gen OharaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Yuika SasataniDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Hideyasu YamadaDivision of Respiratory Medicine, Hitachinaka Medical Center, University of Tsukuba-Hitachinaka General Hospital, Hitachinaka, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Ryugasaki, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan hirosato@md.tsukuba.ac.jp.
National Hospital Organization Mito Medical Center · JPHitachi General Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the majority of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations, first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are ineffective. The second-generation TKI, afatinib, is considered effective in patients with uncommon mutations, however, long-term survivors have been rare. CASE REPORT: We report herein a patient with lung adenocarcinoma harboring double uncommon EGFR L861Q and G719X mutations, who is free of disease 32 months after initiation of afatinib therapy. To our best knowledge, this patient has the longest response among other patients with double uncommon mutations.

conclusionPatients with this type of NSCLC may obtain long-term survival with afatinib.

Indexed as

AllelesMutationAdenocarcinoma of LungAgedAmino Acid SubstitutionErbB ReceptorsFemaleHumansLung NeoplasmsMalePrognosisRadiography, ThoracicTomography, X-Ray ComputedEGFR protein, humanErbB ReceptorsafatinibLong-term survivallung adenocarcinomauncommon EGFR mutations

Identifiers

PMID32354946
PMCPMC7279823
OpenAlexW3022520655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.